
    
      A double-blind, placebo controlled, randomized cross-over single dose escalation study and a
      double-blind, placebo controlled, randomised parallel group 7-days once daily repeat dose
      study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of oral
      H1/H3 dual antagonist compound in healthy male subjects
    
  